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Abstract
Background:  Androgen deprivation therapy leads to a number of adverse effects including
deterioration of the musculoskeletal system and increased risk factors for cardiovascular and
metabolic complications. The purpose of this study is to determine the effects, efficacy, retention
and compliance of a physical exercise intervention in a large established cohort of prostate cancer
patients from the Randomised Androgen Deprivation and Radiotherapy (RADAR) study.
Specifically, we aim to compare short- and long-term effects of a prostate cancer-specific
supervised exercise program to a standard public health physical activity strategy utilizing printed
resources on cardiovascular and metabolic risk factors. Our primary outcomes are
cardiorespiratory capacity, abdominal obesity, and lipid and glycemic control, while secondary
outcomes include self-reported physical activity, quality of life and psychological distress.
Methods/Design: Multi-site randomized controlled trial of 370 men from the RADAR study
cohort undergoing treatment or previously treated for prostate cancer involving androgen
deprivation therapy in the cities of Perth and Newcastle (Australia), and Wellington (New Zealand).
Participants will be randomized to (1) supervised resistance/aerobic exercise or (2) printed
material comprising general physical activity recommendations. Participants will then undergo
progressive training for 6 months. Measurements for primary and secondary endpoints will take
place at baseline, 6 months (end of intervention), and at 6 months follow-up.
Discussion:  This study uses a large existent cohort of patients and will generate valuable
information as to the continuing effects of exercise specifically targeting cardiovascular function and
disease risk, insulin metabolism, abdominal obesity, physical function, quality of life and
psychological distress. We expect dissemination of the knowledge gained from this project to
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reduce risk factors for the development of co-morbid diseases commonly associated with
androgen deprivation therapy such as cardiovascular disease, obesity, metabolic disease and
diabetes, as well as improvements in physical and functional ability, and quality of life.
Trial Registration: ACTRN12609000729224
Background
Advancing age increases the vulnerability to cancer and
the risk for other comorbid conditions (e.g. cardiovascu-
lar disease, diabetes, osteoporosis, arthritis and sarcope-
nia) [1] that can compromise physical function and
independent living, ultimately culminating in death. The
high prevalence of cancer and comorbidity-related condi-
tions, apart from exacting a high personal, family and
community cost, places a heavy burden on the health care
system. Lifestyle interventions that can ameliorate toxici-
ties of treatment, and improve ability to self care are seen
as highly desirable.
Androgen deprivation therapy (ADT) leads to a number of
adverse effects including deterioration of the muscu-
loskeletal system and increased risk factors for cardiovas-
cular and metabolic complications (e.g. negative
lipoprotein profile, reduced insulin sensitivity, abdomi-
nal obesity) [2-7]. Moreover, investigators from four large
recent observational studies, including our own current
Australian cohort, found an increased incidence of myo-
cardial infarction and metabolic complications following
ADT [8-12]. This is of considerable concern to patients
and clinicians as the co-morbidities exacerbated by ADT
become a greater threat to survival than the prostate can-
cer itself.
Regular exercise is established for primary and secondary
prevention of several chronic diseases including cardio-
vascular disease (CVD) and diabetes, and even premature
death [13,14]. The protective effect of physical activity
appears to be greater in individuals at highest risk for type
2 diabetes [15]. Notably, in regards to the risk for prema-
ture death, cardiorespiratory reserve appears to be more
important than other well known CVD risk factors [16].
Men with prostate cancer undergoing ADT are recognized
to gain fat mass, lose lean mass, and be subject to a series
of adverse effects from therapy [5,7,9,17]. Hence these
men could benefit from exercise by reducing risk factors
for metabolic complications and therapy-related co-mor-
bidities [9].
We have previously summarized all exercise interventions
undertaken during and after cancer treatment [18]. Most
of the experimental studies comprised patients with breast
cancer and a mixture of other types of cancer, but did not
include men with prostate cancer undertaking ADT [18].
Moreover, most exercise interventions included very low
subject numbers, limited study designs and short-term
intervention periods with modest or no follow-up peri-
ods. Recently, we [19,20] and others [21,22] in tightly
controlled laboratory-based trials have demonstrated that
exercise can prevent and even reverse adverse effects of
androgen suppression. We have also recently reported
specific exercise guidelines for prostate cancer patients
that could potentially be incorporated in extensive popu-
lation cohorts and community programs benefiting large
numbers of patients [23]. However, to date there has been
no large representative cohort study with prostate cancer
patients undertaking exercise and this should be viewed as
an immediate priority given the potential to reduce treat-
ment toxicity, incidence of co-morbidity, mortality and
substantially improve quality of life and well being. This
study is unique as it applies findings from recent clinical
trials [19-22] to a very large representative cohort of
patients, the Randomised Androgen Deprivation and
Radiotherapy (RADAR) study cohort. The RADAR study,
examines the effect of adjuvant ADT on relapse free sur-
vival as well as other outcome measures in over 1000 men
with prostate cancer at several centers in Australia and
New Zealand. It will also allow us the opportunity to
explore biological questions that would normally be too
expensive to investigate (using data already collected by
the RADAR study). The beneficial outcomes of the exer-
cise intervention interaction, if substantiated, have the
potential to alter clinical practice worldwide.
The purpose of this study is to determine the effects, effi-
cacy, retention and compliance of a physical exercise
intervention in a large established cohort of prostate can-
cer patients from the RADAR study. Specifically, we aim to
compare short- and long-term effects of a prostate cancer-
specific supervised exercise program to educational mate-
rial of physical activity utilizing printed resources on car-
diovascular and metabolic risk factors. Our primary
outcomes are cardiorespiratory capacity, abdominal obes-
ity, and lipid and glycemic control, while secondary out-
comes include self-reported physical activity, quality of
life and psychological distress. Our hypothesis is that
compared to a standard physical activity recommendation
(e.g. perform 30 minutes of moderate/vigorous physical
activity 5 days of the week), the prostate cancer-specific
supervised exercise intervention will elicit superior adap-
tations in: improving physical/cardiorespiratory capacity;
body composition (reducing abdominal fat mass); glyc-
emic control and lipid metabolism; enhancing self-BMC Cancer 2009, 9:419 http://www.biomedcentral.com/1471-2407/9/419
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reported physical activity, quality of life and psychological
distress. This project has the potential to elicit positive
health benefits for large numbers of men with prostate
cancer. It is a lifestyle intervention that allows patients
some control and personal responsibility and, as such,
could easily be expanded to all such patients resulting in
a considerable reduction in morbidity and mortality.
Methods/Design
This is a randomized controlled trial in which all subjects
will receive printed material which describes the impor-
tance of exercise for prostate cancer patients and outlines
basic recommendations to increase their levels of physical
activity (e.g. perform 30 minutes of moderate/vigorous
physical activity 5 days of the week). However, only half
of the subjects will be given access to regular sessions with
an exercise physiologist and access to dedicated Internet
resources over a period of 6 months (group 1). In the sec-
ond 6-month period, group 1 will further have access to a
booklet with detailed information about a home exercise
program but will not receive exercise supervision (Figure
1). The group only receiving printed material about basic
recommendations to increase levels of physical activity
(control condition, group 2) will remain unchanged dur-
ing the 6-month follow-up. This design is based on our
experience over numerous exercise trials and has several
advantages over a "no intervention" control group. First,
in exercise research, subjects allocated to a true control
group will either comply, drop out early, or take up exer-
cise regardless of the instructions to maintain their usual
lifestyle. The result is very low retention or worse, a
severely contaminated dataset. At the completion of the
study, group 2 participants (control condition) will be
given access to all printed and Internet-based resources
(including the booklet with detailed information about a
home exercise prescription) developed during the course
of the study to encourage exercise adoption.
Subjects
370 men from the RADAR study cohort undergoing treat-
ment or previously treated for prostate cancer involving
ADT with no regular exercise (undertaking structured aer-
obic or resistance training less than two times per week)
within the past 6 months will be recruited (Figure 1). Par-
ticipants will have been treated or are currently being
treated with ADT, able to walk 400-m and will require
medical clearance from their physician (general practi-
tioner). Exclusion criteria will include bone metastases,
acute illness or any musculoskeletal, cardiovascular or
neurological disorder that could inhibit or put them at
risk from exercising. Participants with established but
controlled CVD or type II diabetes will not be excluded
CONSORT diagram Figure 1
CONSORT diagram.
RADAR Study Cohort Database
Screening/Baseline testing
Stratification/Randomization
Supervised resistance/aerobic 
exercise (Intervention Arm)
General physical activity 
recommendation (Control Arm)
6-month post-test 6-month post-test
6-month follow-up 6-month follow-up BMC Cancer 2009, 9:419 http://www.biomedcentral.com/1471-2407/9/419
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from participation given the large benefits of exercise.
Subjects will be recruited from the RADAR study database
via a letter of invitation from their specialist and will then
be contacted by an exercise physiologist accredited by the
Australian Association for Exercise and Sport Science
(AAESS) or Sport & Exercise Science New Zealand
(SESNZ) in their respective geographical areas. Those
entering the study will complete a health history ques-
tionnaire and undertake baseline measures prior to being
randomized to either the supervised exercise group or the
standard physical activity recommendation group. The
protocol has been approved (ID: 3636-GALVÃO) by the
University Human Research Ethics Committee and all
subjects will provide written informed consent.
Randomization and Stratification
Patients will be randomly allocated to the two treatment
arms: (1) exercise and (2) standard physical activity rec-
ommendation in a ratio of 1:1, subject to maintaining
approximate balance regarding stratification for age (<69,
69-74, >74), original RADAR study arm [(A) 6-month
ADT and radiation; (B) 6-month ADT, radiation and 18-
month bisphosphonate; (C) 18-month ADT and radia-
tion; and (D) 18-month ADT, radiation and 18-month
bisphosphonate], current levels of testosterone (<3, 3-8,
>8), and waist circumference (< or > than 102 cm) (Figure
2).
Exercise Intervention (group 1)
The exercise program will be undertaken twice weekly in
small groups of participants and will be supervised by the
exercise physiologist over 6 months. This group will also
have access to Internet resources where they will be able to
input information regarding their weekly physical activity.
Sessions will comprise aerobic and resistance exercise
using a variety of equipment. In addition, 2 exercise ses-
sions will be completed at home each week comprising
aerobic exercise (e.g. walking). The clinic sessions, which
will commence with a warm-up and finish with a cool-
down (comprising exercise on a cycle ergometer or tread-
mill at a relatively low intensity and stretching activities),
will take approximately 60 minutes and will be conducted
in local exercise facilities. The moderate- to high-intensity
progressive resistance training regime will include 7 exer-
cises that target the major upper and lower body muscle
groups, which we have used previously in a number of
studies including those with prostate cancer patients
[19,24-27]. The exercises are the chest press, seated row,
shoulder press, leg press, leg extension, leg curl and
abdominal crunches. The resistance exercise program is
designed to progress from 12 to 6-repetition maximum
(RM) for 2 to 4 sets per exercise. Each clinic session will
include 20-30 minutes of aerobic exercise using various
modes such as walking or jogging on a treadmill, cycling
or rowing stationary ergometers. Target intensity will be
70-85% of estimated maximum heart rate with individual
heart rate monitors provided for each participant. During
the 6-month follow-up period, this group will have access
to a booklet with detailed information about a home exer-
cise prescription but will no longer receive exercise super-
vision. The home exercise program combines resistance
training (using body weight, rubber bands, and objects
around the house as a resistance and is designed to repli-
cate the exercises performed in the supervised sessions),
aerobic training, and flexibility exercises.
Standard Physical Activity Recommendation (group 2)
The standard physical activity recommendation group
(control condition) will be instructed via printed material
to perform the general recommendation of 30 minutes of
moderate/vigorous physical activity 5 days per week (150
minutes per week of moderate activity) during the initial
6-month period as well as the 6-month follow-up period.
At the completion of the study, this group will be given
access to the booklet with detailed information about a
home exercise prescription and internet resources devel-
oped during the course of the study to encourage exercise
adoption. Instruction on performing the home-based
Exercise interventions and timeline Figure 2
Exercise interventions and timeline.
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exercises will be provided by the exercise physiologist
(this will take place at the end of the 6-month follow-up).
Study Endpoints
Measurements will take place at baseline, 6 months (end
of the supervised exercise intervention period), and at 6
months follow-up. The assessment at 6 months follow-up
is to determine the long-term effects and whether differ-
ences observed directly following the intervention are
maintained in the exercise group when the booklet of
standard physical activity recommendations is supple-
mented with the home exercise prescription.
Aerobic Walking Capacity
As a measure of quantitative aerobic walking endurance
capacity, subjects will undertake a timed 400-m walk, 10
laps out and back over a 20-m corridor path [19,28,29].
Anthropometric Measures/Abdominal Obesity
Central adiposity will be assessed by waist circumference
(WC) and hip circumference (HC) will also be deter-
mined [30]. WC will be measured at the level of the nar-
rowest point between the lower costal (rib) border and
the iliac crest. HC will be measured at the level of the
greatest posterior protuberance of the buttocks which usu-
ally corresponds anteriorly to the level of the symphysis
pubis. The waist-to-hip ratio will be determined and has
been shown to be a strong indicator of atherosclerosis and
risk of myocardial infarction [31,32]. Body mass index
(kg/m2) will also be used to assess weight (kg) relative to
height (m) and is a good indicator of obesity and meta-
bolic and health-related problems.
Blood Markers
Testosterone, prostate specific antigen (PSA), insulin,
lipid profile, glucose and HbA1c levels will be measured
commercially by accredited Australian National Associa-
tion of Testing Authorities (NATA) and International
Accreditation New Zealand (IANZ) laboratories.
Self-reported Physical Activity
Self-reported physical activity will be assessed by the lei-
sure score index from the Godin Leisure-Time Exercise
Questionnaire. Overall physical function will also be
assessed qualitatively using the SF-36 physical function
sub-scale. In addition, participants will wear a pedometer
for seven days at the three measurements time points to
obtain a quantitative measure of steps per day.
Quality of Life, Falls Self-Efficacy and Psychological 
Distress
Health-related quality of life will be measured using the
EORTC QLQ-C30 and EORTC QLQ-PR25 as well as a
health history questionnaire [3,33]. This validated instru-
ment is an integrated system to assess quality of life in
cancer patients and has been extensively employed in
clinical trials [34]. The Brief Symptom Inventory-18 (BSI-
18) will be used to assess psychological distress (Anxiety,
Depression and Somatisation) [35]. Falls self-efficacy was
determined using the activities-specific balance (ABC)
confidence scale [36].
Nutrition
Participants will be encouraged to maintain customary
activity and dietary patterns and the mini nutritional
assessment (MNA) instrument will be used to monitor
nutritional status [37].
Lower Body Physical Function
Lower body performance will be assessed by the repeated
chair rise test, where subjects rise to a standing position
five times as fast as possible without using their hands for
support [19,25].
Additional Measures for the Perth Site
In addition to the above measures, participants at the
Perth site will have the following assessments undertaken
at the same 3 time points.
Body Composition
Whole body lean mass (LM), fat mass (FM), and percent
fat will be assessed by dual-energy X-ray absorptiometry
(DXA, Hologic Discovery A, Waltham, MA). From the
whole body scan, upper limb, lower limb, and trunk LM
and FM will be derived by manipulating segmental lines
according to anatomical landmarks [38]. Upper limb LM
and lower limb LM will then summed to derive appendic-
ular skeletal muscle [39].
Muscle Strength
Dynamic concentric muscle strength will be measured
using the one repetition maximum (1-RM) method. The
1-RM is the maximal weight an individual can move
through a full range of motion without change in body
position other than that dictated by the specific exercise
motion [25].
Balance and Risk of Falling
A Neurocom Smart Balancemaster (Neurocom, OR, USA)
will be used to assess static and dynamic balance. This
device measures ground reaction force to track whole
body centre of pressure and a tilting visual field and sup-
port platform to separate the visual, somatosensory and
vestibular balance sense of the patient. As a measure of
dynamic balance, subjects will also walk backwards 6-m
and time taken will be assessed using electronic timing
gates [25].BMC Cancer 2009, 9:419 http://www.biomedcentral.com/1471-2407/9/419
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Calculation of Sample Size and Statistical Analysis
The sample size estimate was based on projected changes
in aerobic walking capacity (cardiorespiratory fitness) as
measured by the 400-m walk as this study endpoint has
been shown to be a strong predictor of mortality, CVD
and mobility limitations in older adults [28,40,41]. To
achieve 80% power at α = 0.05 (two-tailed), 142 subjects
per group are required to demonstrate a 0.33 SD differ-
ence between groups at the end of the 6-month interven-
tion and follow-up periods. Previous experience with
exercise trials indicates an attrition rate of up to 30% over
the course of the study period. Therefore, to ensure that
we have sufficient subject numbers at the end of the inter-
vention and follow-up periods, 185 subjects will be rand-
omized to each of the groups (N = 370). Regarding the
other outcomes, a sample size of 370 will account for
expected differences. Data will be analysed using the SPSS
statistical software package. Analyses will include stand-
ard descriptive statistics, Student's t tests, correlation and
regression, and two-way (group × time) repeated meas-
ures ANOVA to examine differences between groups over
time. All tests will be two-tailed and an alpha level of 0.05
will be applied as the criterion for statistical significance.
Discussion
This will be the first exercise intervention undertaken in a
large cohort of prostate cancer patients and will produce
the strongest efficacy information to date. As this project
uses a very large and representative cohort of patients and
is longer than previous investigations in the area of exer-
cise and cancer, we will gain valuable information as to
the continuing effects of exercise specifically targeting car-
diovascular and muscle function and disease risk, insulin
metabolism, abdominal obesity, physical function, qual-
ity of life and mental health. Specifically we will be able
to: 1) compare a large-scale supervised program of exer-
cise to standard physical activity recommendations, and
2) examine the effect that a non-supervised, exercise-spe-
cific home-based program has on maintaining gains
derived from supervised training. Importantly, this simple
and cost effective intervention strategy may provide simi-
lar benefits to pharmaceutical interventions without
exposing patients to additional potential side effects and
cost. In terms of advancement of prostate cancer care, we
expect dissemination of the knowledge gained from this
project to reduce risk factors for the development of co-
morbid diseases such as CVD, obesity, metabolic disease
and diabetes, as well as improve physical and functional
ability, and quality of life. In addition, such positive
effects could significantly reduce health care costs. Lastly,
by incorporating an extensively studied patient cohort,
the RADAR cohort, other subsequent biological questions
may be possible to address.
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